Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
PlenOptika is a pioneering medical technology company dedicated to eradicating preventable vision loss worldwide. Born from research at MIT, their mission is to create and deploy sight-saving technologies so everyone can see their world clearly. Their flagship product, QuickSee™, is recognized as the world’s most accurate handheld wavefront autorefractor, designed to provide fast, reliable, and affordable vision assessments in diverse settings, from urban clinics to remote villages. PlenOptika focuses on innovative solutions that empower eye care professionals to reach more patients and deliver high-quality care, ultimately transforming lives through better vision. Their technology is used by clinicians, optical shops, and screening programs in over 45 countries.
Serves as the global headquarters, housing research and development, product innovation, strategic planning, manufacturing oversight, and global operations management for PlenOptika's sight-saving technologies.
Strategically located in Boston, a leading global hub for medical technology, life sciences, and biotech innovation, providing PlenOptika with access to world-class talent, research institutions, and collaborative opportunities.
A mission-driven, collaborative, and innovative environment. Employees are passionate about developing impactful technologies to address global vision care challenges, fostering a culture of scientific excellence and continuous improvement.
The Boston headquarters is pivotal for PlenOptika's innovation pipeline, leveraging the rich local ecosystem of academic institutions (like nearby MIT where the company originated), medical research facilities, and a skilled talent pool in engineering, optics, and healthcare.
PlenOptika has a significant global impact, with its QuickSee™ technology utilized by eye care professionals and organizations in over 45 countries across North America, Europe, Asia, Africa, and Latin America. Their global functions include establishing distribution partnerships, providing training and support for their devices, and collaborating with NGOs and healthcare providers to improve access to vision screening and refractive error correction worldwide, particularly in underserved regions.
1284 Soldiers Field Road
Boston
MA
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, PlenOptika' leadership includes:
PlenOptika has been backed by several prominent investors over the years, including:
PlenOptika's founding executive team continues to lead the company. No major high-level executive hires or departures have been publicly announced in the past 12 months. The company's recent Series B funding (November 2023) is aimed at scaling operations and market expansion, which may lead to future team growth.
Discover the tools PlenOptika uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
PlenOptika likely uses standard professional email address formats. Common patterns for companies of this nature include [first].[last]@plenoptika.com or [first_initial][last]@plenoptika.com.
[first].[last]@plenoptika.com
Format
shivang.dave@plenoptika.com
Example
85%
Success rate
plenoptika.com • November 14, 2023
PlenOptika announced the successful closure of its $10 million Series B funding round. The investment was led by Participatiemaatschappij Oost Nederland (Oost NL), with significant participation from existing investors Material Impact and Aspire Health Science, alongside new investor HOYA Vision Care. The funds will be used to scale manufacturing, expand into new markets, and further develop its product pipeline....more
plenoptika.com • May 17, 2023
A study published in Translational Vision Science & Technology (TVST) highlighted QuickSee's high success rate (97%) and accuracy in measuring refractive error in children aged 3-12 years. The device outperformed other handheld screeners and aligned closely with clinician subjective refraction, underscoring its significant potential for early detection of vision problems in pediatric populations globally....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including PlenOptika, are just a search away.